The best-studied trial for targeted cancer therapies that exploits this principle is the use of poly-ADP ribose polymerase (PARP) inhibitor against tumor with breast cancer gene 1 (BRCA1) or 2 (BRCA2) mutations [61]. The gene discussed is PARP1; the disease is neoplasm.